Duchenne News Tags: Edgewise Therapeutics

July 14, 2022
On July 12, 2022, Edgewise Therapeutics shared a press release announcing the opening of the CANYON Phase 2 clinical trial of their investigational compound, EDG-5506, in individuals with Becker muscular...
Edgewise Duchenne News
June 21, 2022
On June 20, 2022, Edgewise Therapeutics announced positive results from the ARCH open label study of EDG-5506.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open